Australia - English - Department of Health (Therapeutic Goods Administration)

aa-med pty ltd - calcium chloride dihydrate, quantity: 1.286 g; magnesium chloride hexahydrate, quantity: 0.51 g; sodium chloride, quantity: 28.2 g; glucose monohydrate, quantity: 5.512 g (equivalent: glucose, qty 4.987 g); potassium chloride, quantity: 1.492 g - injection, solution - excipient ingredients: water for injections; dibasic sodium phosphate dihydrate; dilute hydrochloric acid - a continuous renal replacement therapy (crrt) replacement fluid used in intensive care units for the treatment of acute kidney injury.

Australia - English - Department of Health (Therapeutic Goods Administration)

aa-med pty ltd - magnesium chloride hexahydrate, quantity: 0.51 g; calcium chloride dihydrate, quantity: 1.286 g; sodium chloride, quantity: 28.2 g; glucose monohydrate, quantity: 5.512 g (equivalent: glucose, qty 4.987 g); potassium chloride, quantity: 0.746 g - injection, solution - excipient ingredients: water for injections; dibasic sodium phosphate dihydrate; dilute hydrochloric acid - a continuous renal replacement therapy (crrt) replacement fluid used in intensive care units for the treatment of acute kidney injury.

Australia - English - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - sodium nitroprusside, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - sodium nitroprusside concentrated injection is indicated for: ,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside. ,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate. ,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ).  acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings , precautions , dosage and administration , and adverse reactio

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - bumetanide (unii: 0y2s3xuq5h) (bumetanide - unii:0y2s3xuq5h) - bumetanide injection is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. almost equal diuretic response occurs after oral and parenteral administration of bumetanide. therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. successful treatment with bumetanide following instances  of allergic reactions  to  furosemide  suggests a lack of cross-sensitivity. bumetanide is contraindicated in anuria. although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the conditi

Israel - English - Ministry of Health

teva medical marketing ltd. - glucose as monohydrate - solution for injection - glucose as monohydrate 10 % - glucose - glucose - as intravenous injection: dextrose 10 % injection is indicated as a source of water and calories. as parenteral nutrient: dextrose 10 % injection is indicated as a caloric component in parenteral nutrition regimen. it is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: 1) the alimentary tract cannot should not be used. 2) gastrointestinal absorption of protein is impaired, or 3) metabolic requirements for protein are substantially increased, as extensive burns.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium acetate, quantity: 1.28 g/l; sodium chloride, quantity: 2.34 g/l; magnesium acetate tetrahydrate, quantity: 320 mg/l; glucose, quantity: 50 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - plasma-lyte 56 and 5% glucose iv infusion is indicated as a source of water, electrolytes and calories or as an alkalinising agent. plasma-lyte 56 in 5% glucose is indicated as a source of water and electrolytes or as an alkalinising agent.

Israel - English - Ministry of Health

lapidot medical import and marketing ltd - glucose as monohydrate - solution for infusion - glucose as monohydrate 10 % - glucose - glucose - carbohydrate infusion therapy : - hypoglycaemic situations, - hypertonic dehydration , - hypertonic electrolyte disturbances. vehicle solution for supplementary medication.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; lactic acid as sodium 1.68 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 13.6 g/l; calcium chloride dihydrate 0.184 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; glucose monohydrate (as anhydrous) 22.7 g/l; calcium chloride dihydrate 0.184 g/l; lactic acid as sodium 1.68 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium bicarbonate 2.10 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.